TA53 |
Diabetes (types 1 and 2) - long acting insulin analogues (TA53) |
|
-
-
diabetes
Fast, easy summary view of NICE guidance on 'diabetes'
-
-
-
The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes
NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person:
- needs help with his or her insulin injections from a carer or healthcare professional, or
- has repeated and unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or
- would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.
The recommendations in this technology appraisal relating to type 2 diabetes have been replaced by recommendations in the Diabetes - type 2 (update) clinical guideline published in May 2008. Please note that the recommendations in this technology appraisal relating to type 1 diabetes have not changed.
-
Other information
- TA53 Diabetes (types 1 and 2) - long acting insulin analogues: guidance (web format)
- TA53 Diabetes (types 1 and 2) - long acting insulin analogues: summary
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: diabetes
How this guidance was produced
Background information
- Review decision - October 2007
- Review proposal
- Assessment Report: the clinical effectivess and cost effectiveness of long acting insulin analogues for diabetes
- Addendum to assessment report: the cost-effectiveness of long-acting insulin analogue, insulin glargine
- TA53 Diabetes (types 1 and 2) - long acting insulin analogues: media briefing
This page was last updated: 10 April 2013
-
Guidance formats
- Web format
- Full Guidance (PDF)
- TA53 Arweiniad ar ddefnyddio analogau inswlin hirbarhaol ar gyfer trin clefyd siwgr - inswlin glargin: deall canllawiau NICE
Diabetes (types 1 and 2) - long acting insulin analogues
Information for the public
-
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.